# CROSS-INDUSTRY Organizations

## RDD Conferences—Bringing the pulmonary and nasal world together

**The Organizers of the Respiratory Drug Delivery Conference Series**

Respiratory Drug Delivery (RDD®) Europe 2027 (www.rddonline.com/rddeurope2027) will take place in Antibes, France, April 27-30, 2027. Now is the time to nominate speakers, design workshops and develop poster abstracts.

Before looking ahead, let's recap RDD 2026 (www.rddonline.com/rdd2026) held in Phoenix, Arizona, US, to whet your appetite. It was a highly interactive and informative conference with more than 400 delegates from 23 countries exchanging ideas about the latest science and technology driving inhaled and nasal drug product development. New exhibitors and fresh faces in the audience explored cutting-edge science with speakers and other delegates during the various networking opportunities. The vibe was energetic and inclusive, with themed knowledge spaces connecting people and organizations around shared interests.

### Highlights from RDD 2026

Drawing on his extensive track record of innovations, Jeffry Weers presented the keynote address, "Implications of the iBCS on Molecule Design and Particle Engineering of Medicines for Inhalation," concluding that the inhalation Biopharmaceutics Classification System provides a valuable framework for developing new delivery systems beyond those traditionally used to treat asthma and COPD.

"Disrupt, Repurpose, Deliver" explored the changing inhaled and nasal pipeline with a central message that future success will depend not only on promising molecules, but also on adaptable technology platforms that can support multiple products and development pathways. Nitesh Kunda and Francesca Buttini exemplified the changing landscape with insightful presentations sharing progress in inhaled drug delivery for non-small cell lung cancer and repurposing GLP-1 receptor agonists for pulmonary and nasal delivery. Subsequent sessions explored why "New Molecules Need New Methods" including a translational approach designed to improve prediction of clinical bioavailability as well as developing analytical best practices for respiratory biologics.

Jan de Backer chaired the "Data Driven Design in Respiratory Product Development" Explore with Experts Panel, which revisited the case for connected inhalers, the growing role of *in silico* modeling, artificial intelligence and US Food and Drug Administration (FDA) regulatory acceptance of these advanced approaches. Additional sessions examined "Designing Intranasal Delivery Systems for Deposition, Retention, and Scale" to support commercial success as well as "Next-Generation DPI Therapies" focused on development of "Powders That Perform," which included a presentation by the FDA's Susan Boc, titled "Exploring Aerosolized Powder Behavior in Dry Powder Inhalers using Advanced Imaging Techniques."

Delegates who stayed until the end were rewarded with a thought-provoking "Explore with Experts" session on: "The MDI at 70: Evolving Science and Regulation." Industry (Tom Daly, Lucas Silva, Nick Smalley and Stephen Stein) and FDA representatives (Elizabeth Bielski, Bryan Newman and Markham Luke) collectively highlighted how new imaging and analytical tools could aid in assessment of bioequivalence (BE) and the transition to next generation propellants. Having foreshadowed this at RDD 2026, the FDA subsequently announced updated Product Specific Guidances (PSGs) for metered dose inhalers (MDIs), making priming, spray pattern and plume geometry unnecessary if Single Actuation Content and realistic aerodynamic particle size distribution studies were conducted as part of BE packages.

Workshops, posters and corporate exhibits greatly contributed to the success of RDD 2026, which also honored Anthony Hickey as the 2026 Charles G. Thiel Award winner, and saw the University of Alabama's Teri Ross presented with the 2026 VCU RDD Peter R. Byron Graduate Student Award for her work exploring how optical photothermal infrared microscopy could be used to characterize DPI blends.

## Extended online access to RDD 2026

Delegates who struggled to see all the content during the conference have on-demand access to presentations, posters and workshops until December 31, 2026. RDD 2026 delegates and subscribers can use their existing log-in credentials to access the RDD Publications database of over 3,100 papers covering 38 years of pulmonary and nasal drug development (www.rddonline.com/publications).

Our sincere thanks to all delegates, presenters, sponsors, media partners, reviewers, moderators and helpers at RDD 2026.

## RDD Europe 2027: Plan to participate

RDD Europe 2027 will be held at the Palais des Congrès Antipolis Antibes (Nice), France, April 27-30, 2027. It's an easily accessible venue with plenty of accommodation options nearby. The three-day format will have almost all the features described above with the emphasis on pioneering science and opportunities for networking in a collegial and business-friendly setting.

The program will be built around invited presentations in each key area covered by the RDD Conference series. Specifically:

- Bench to Bedside: New therapeutic targets, emerging therapies including biotherapeutics, diagnostics and clinical approaches to improve pulmonary health for patient populations.
- Pressurized Inhalers: Progress in alternative propellants and formulations, hardware, environmental impact.
- Dry Powder Inhalers: Advances in pharmaceutical engineering, formulation science, device design and industrialization.
- Nasal Delivery: Intranasal platforms for local, systemic and nose to brain delivery.
- Soft-Mist Inhalers & Nebulizers: Breakthroughs in aqueous-based device technologies.
- Inhalation Innovation: Cross-platform advances in regulatory science, connectivity and digital health, modeling, advanced data analytics, sustainability and other emerging topics.

In response to feedback requesting more inclusion of early stage pulmonary and nasal research from biotech, start-ups and entrepreneurs, the Program Committee welcomes proposals and speaker suggestions highlighting Rising Stars in Respiratory Science.

## RDD Europe 2027 Deadlines and details

There are numerous ways to participate. More details and submission links are available at www.rddonline.com/rddeurope2027.

- Early-bird and waived graduate student registration to eligible students.
- Conference supporters, workshop presenters and exhibitors should sign up now for maximum visibility.
- Integrated poster and exhibition sessions for the duration of the conference. Poster abstract submission deadline: January 15, 2027.
- Attend delegate-selectable workshops providing practical and interactive demonstrations of innovative technologies, products and services.
- The VCU RDD Peter R. Byron Graduate Student Award. Eligibility is automatic upon acceptance of a qualifying poster abstract.

RDD has a long history of bringing the pulmonary and nasal drug delivery community together with substance and style. We invite you to be a part of it by actively planning to participate in RDD Europe 2027 next April.